RVL Pharmaceuticals (RVLP) Stock Analysis

What RVL Pharmaceuticals does

RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids. The company, whose corporate headquarters are located in Bridgewater, New Jersey, underwent a name change in January 2022, transitioning from its former identity as Osmotica Pharmaceuticals plc.

Key metrics

ETFs linked to RVLP

Broad-market and Healthcare sector ETFs an investor holding RVL Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RVLP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for RVL Pharmaceuticals?

RVL Pharmaceuticals trades under the ticker RVLP on NASDAQ.

Which exchange is RVLP listed on?

RVLP is listed on NASDAQ.

What sector does RVL Pharmaceuticals operate in?

RVL Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RVLP in a portfolio?

PortView shows RVLP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.